United Kingdom Myomectomy Market Size, Share, and COVID-19 Impact Analysis, By Type (Abdominal, Hysteroscopic, and Laparoscopic), By Product (Laparoscopic Power Morcellators, Harmonic Scalpel, Laparoscopic Sealer, and Others), and UK Myomectomy Market Insights, Industry Trend, Forecasts to 2035

United Kingdom Myomectomy Market Size Forecasts to 2035

• The United Kingdom Myomectomy Market Size Was Estimated at USD 35.3 Million in 2024
• The UK Myomectomy Market Size is Expected to Grow at a CAGR of around 10.14% from 2025 to 2035
• The UK Myomectomy Market Size is Expected to Reach USD 102.1 Million by 2035

According to a Research Report Published by Spherical Insights & Consulting, the UK Myomectomy Market Size is anticipated to reach USD 102.1 Million by 2035, growing at a CAGR of 10.14% from 2025 to 2035. The myomectomy market is expanding due to rising uterine fibroid cases, increasing demand for fertility-preserving, minimally invasive treatments like laparoscopic and robotic-assisted procedures, and innovations in incisionless, high-energy wave technologies enhancing safety and recovery.

Market Overview

The UK Myomectomy Market Size refers to a surgical excision of uterine fibroids while preserving the uterus is identified as a non-economic sector. The treatments for uterine fibroids, which are non-cancerous growths in the uterus that can result in a variety of symptoms and consequences, are included in this market along with the associated technologies, operations, and services. The increasing incidence of uterine fibroids, along with increasing demand for less invasive treatment methods and the increasing prevalence of myomectomy, are key factors driving myomectomy growth. For example, uterine fibroids were prevalent, with almost two out of three women experiencing at least one fibroid at some point in their lives, and they most frequently affected women between the ages of 30 and 50, according to statistics provided by the UK NHS in September 2022. Therefore, it is anticipated that over the forecast period, the increasing frequency of uterine fibroids would increase the use of laparoscopic myomectomy. Furthermore, it is anticipated that growing research on urological disorders will accelerate segmental expansion over the course of the projected period. The increasing demand for minimally or non-invasive uterine fibroid treatments is encouraging the trend in technologies with laparoscopic and robotically assisted myomectomies. New incisionless devices using high-energy waves are producing great safety, comfort, and fertility preservation benefits for reproductive-age women, giving new material safety with adherence to product compliance. Collectively, these innovations underscore our potential for growth in this market during the forecast period.

Report Coverage

This research report categorizes the market for the UK myomectomy market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the United Kingdom myomectomy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the United Kingdom myomectomy market.

Driving Factors

The rising prevalence of uterine fibroids in the UK is a key market driver that drives the demand for effective methods of myomectomy. Awareness and improved screening methods have encouraged more women to seek fertility-preserving therapies and generated more diagnoses. Myomectomy, which manages uterine anatomy, has also become a preferred intervention option. Also important are developments in medical imaging, which both improve detection rates and, subsequently, create demand for effective treatment options that promote market growth.

Restraining Factors

The high rate of fibroids recurring after myomectomy, which affects up to 50% of patients, is a major commercial constraint. Further procedures are required due to this recurrence, which frequently discourages patients from originally opting for surgery. The cost of repeat surgery is an additional constraint, particularly in low-resource environments, which limits growth in the market by diminishing patient belief in the long-term impact of surgical care. These factors hamper the myomectomy market during the forecast period.

Market Segmentation

The United Kingdom myomectomy market share is classified into type and product.

• The abdominal segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The United Kingdom myomectomy market is segmented by type into abdominal, hysteroscopic, and laparoscopic. Among these, the abdominal segment held the largest market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The increase in uterine fibroids requires recommending myomectomy treatments. This method is the most prevalent & frequently used method for fibroid treatment. Simply put, this surgical treatment is the standard care for removing fibroids, while preserving the uterus and allowing patients to continue to be fertile, making it a reliable, permanent method for uterine fibroid treatment.

• The laparoscopic sealer segment held the highest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The United Kingdom myomectomy market is segmented by product into laparoscopic power morcellators, harmonic scalpel, laparoscopic sealer, and others. Among these, the laparoscopic sealer segment held the highest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. more individuals are opting for myomectomy procedures due to their less invasive nature compared to traditional surgery, which is associated with smaller incisions, less bleeding, shorter hospital stays, and faster recovery times. The use of laparoscopic sealers also increases surgical precision and decreases the risk of complications as they allow for accurate tissue sealing and cutting.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom myomectomy market and a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Halt Medical, Inc.
• Boston Scientific Corporation
• CooperSurgical Inc.
• Smith & Nephew plc
• Medtronic
• Stryker Corporation
• Hologic Inc.
• Karl Storz
• Richard Wolf GmbH
• CONMED Corporation
• Intuitive Surgical Inc
• Others

Key Target Audience

• Investors
• Market players
• End-users
• Government Authorities
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at United Kingdom, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the United Kingdom myomectomy market based on the below-mentioned segments:

United Kingdom Myomectomy Market, By Type

• Abdominal
• Hysteroscopic
• Laparoscopic 

United Kingdom Myomectomy Market, By Product

• Laparoscopic Power Morcellators
• Harmonic Scalpel
• Laparoscopic Sealer
• Others